Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 168

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 168
---
 value of the Company’s convertible senior notes and its TLA Term Loan are calculated utilizing market quotations from an over-the-counter trading market for these notes (Level 2). The fair value of the Company’s acquisition-related contingent consideration is reported at fair value on a recurring basis (Level 3). The carrying amount of equity investments and convertible notes receivable without readily determinable fair values are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments.

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 23

At June 30, 2025, the carrying values and fair values of the following financial assets and liabilities were as follows (in thousands):Carrying ValueFair Value Measurements UsingLevel 1Level 2Level 3Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:Financial Assets:Equity investments$7,750 $— $— $7,750 Convertible notes receivable$2,500 $— $— $2,500 Financial Liabilities:   Acquisition-related contingent consideration$17,209 $— $— $17,209 Financial Liabilities Measured at Amortized Cost:Term loan A facility due March 2028$97,828 $— $98,256 $—    2.125% convertible senior notes due 2029 (1)$280,267 $— $281,419 $—    0.750% convertible senior notes due 2025 (2)$202,397 $— $201,113 $— (1) The closing price of the Company’s common stock as reported on the Nasdaq Global Select Market was $23.90 per share on June 30, 2025, compared to a conversion price of $39.56 per share. At June 30, 2025, as the conversion price was above the stock price, the requirements for conversion have not been met. (2) The 0.750% Convertible senior notes matured and were repaid on August 1, 2025.Financial Assets and Liabilities Measured at Fair Value on a Recurring BasisEquity and Convertible Note InvestmentsThe Company holds strategic investments in clinical and preclinical stage privately-held biotechnology companies in the form of equity and convertible note investments as follows (in thousands